Prof. Binlin Ma 马斌林
Chief Physician, Professor
Head and Neck Surgery, Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionCurrent positions:Chief Expert for Breast and Thyroid Cancer
Checked against a public report (检索 2026-11-15). Positions change; the hospital's website is the final word.
Clinical focus: Diagnosis and treatment of breast, thyroid, and head and neck tumors. Expertise includes early detection, precise localization for surgery, minimally invasive techniques, and reconstructive procedures.
Dr. Ma is a Professor and Chief Physician who graduated from Xinjiang Medical University in 1984. Dr. Ma studied clinical surgical oncology at Nihon University School of Medicine in Japan (1992–1993). Currently serving as Director of the Breast and Head and Neck Surgery Department, Dr. Ma focuses on research and clinical care for breast, thyroid, and head and neck malignancies.
Professional roles
- Member, Breast Cancer Professional Committee, China Anti-Cancer Association
Name order: in Chinese the family name comes first (Ma Binlin). Papers usually list the name as Binlin Ma or Ma B.
Selected publications
61 papers on PubMed matched by name and affiliation; 34 as first or senior author since 2016. Most recent first- or senior-author papers:
- Anal Chim Acta, 2026 (senior author): Morphological saliency prior-guided band-aware multi-modal disease diagnostic fusion network for vibrational spectroscopy. PubMed 42618105
- Clin Exp Pharmacol Physiol, 2026 (senior author): Targeting RAB27A Enhances Pembrolizumab Sensitivity and Alleviates Immune Escape via Inactivation of the PI3K/Akt/mTOR Pathway in Triple-Negative Breast Cancer. PubMed 42825459
- Am J Cancer Res, 2026 (senior author): TRIM68 regulates ubiquitinated degradation of Rabex-5 and plays a role in progression of breast cancer through Rab5-Rac1. PubMed 42465004
- Front Oncol, 2026 (senior author): Deciphering the potential of the C-reactive protein-albumin-lymphocyte index as a prognostic biomarker in malignancy: a systematic review and meta-analysis. PubMed 42100433
- Oncol Lett, 2026 (senior author): Preoperative lymphocyte-albumin-monocyte index as an inflammation- and nutrition-based predictor of overall survival in triple-negative breast cancer: A retrospective cohort study. PubMed 41684352
- Front Oncol, 2025 (senior author): Preoperative prediction of HER2 expression and sentinel lymph node status in breast cancer using a mammography radiomics model. PubMed 40535132
- Discov Oncol, 2025 (senior author): Integrative transcriptomic and single-cell analysis reveals IL27RA as a key immune regulator and therapeutic indicator in breast cancer. PubMed 40450602
- Breast Cancer, 2025 (senior author): c-Myc knockdown restores tamoxifen sensitivity in triple-negative breast cancer by reactivating the expression of ERα: the central role of miR-152 and miR-148a. PubMed 40029493
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion